There were few surprises in PhRMA's response to the Center's Report on Lobbying. "It misses the mark when it comes to efforts by America's pharmaceutical research companies to educate lawmakers," said Ken Johnson, Senior Vice President. "Our priority has always been to help advance patient care and we have supported policies and programs that bolster patient access to safe and effective medicines," he said.
But then how about the $19+ million in political contributions?
For more, read today's balanced Los Angeles Times article.
